Clinical trials: HEPATITIS C (HCV)
Hepatitis C, Chronic
An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients
This prospective, national, multicenter, non-interventional study examined the use of triple combination therapy with boceprevir, pegylated interferon (peginterferon) alfa-2a and ribavirin in re-treating participants with…
- Trial name
- NCT02118597
- Testing
- Boceprevir, Simeprevir, Pegylated Interferon (Peginterferon) Alfa-2a
- Where
- 7 sites in Hungary
- Volunteers
- 19 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
Clinical Study With Silymarin in the Patients With Chronic Hepatitis C Infection Who Failed Conventional Antiviral Therapy
The purpose of this study is to determine the effectiveness of silymarin 700 mg thrice daily and assess the safety in patients with hepatitis C virus infection compared to a placebo.
- Trial name
- NCT01258686
- Testing
- Silymarin
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- Bukwang Pharmaceutical
Chronic Hepatitis c
The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects
The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects
- Trial name
- NCT03673696
- Testing
- HEC74647PA Capsule
- Where
- China
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Chronic Hepatitis C
Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon
This multicenter study was to evaluate subjects with chronic genotype 2 or 3 HCV infection who were interferon (IFN) ineligible, IFN intolerant or unwilling to take IFN.
- Trial name
- POSITRON (NCT01542788)
- Testing
- SOF, RBV
- Where
- 63 sites in United States, Australia and 3 more
- Volunteers
- 278 people
- Sponsor
- Gilead Sciences
Hepatitis C, Hepatitis C, Chronic
Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin
Chronic hepatitis C infection is one of the leading causes of chronic liver disease in the United States. Approximately one-third of patients with hepatitis C infection develop cirrhosis of the liver, which can lead to liver…
- Trial name
- NCT00039962
- Testing
- thymalfasin (thymosin alpha 1), PEGinterferon alfa-2a
- Where
- 56 sites in United States, Puerto Rico
- Volunteers
- 500 people
- Sponsor
- SciClone Pharmaceuticals
Chronic Hepatitis C Infection
Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3
This study is to assess the safety and tolerability of sofosbuvir (SOF) 400 mg with and without ribavirin (RBV) and/or with and without pegylated interferon alfa-2a (PEG) in subjects with genotype 1, 2 or 3 hepatitis C (HCV)…
- Trial name
- NCT01260350
- Testing
- SOF, RBV, PEG
- Where
- 2 sites in New Zealand
- Volunteers
- 292 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C, CHC
A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C
A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Treatment-Naïve Adult Subjects With Genotype 1 Chronic Hepatitis C
- Conditions
- Chronic Hepatitis C, CHC, HCV, Hepatitis C
- Trial name
- NCT01842451
- Testing
- VX-135, Daclatasvir
- Where
- 2 sites in New Zealand
- Volunteers
- 23 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatitis C, Chronic, Hepacivirus
Satisfaction in Patients Receiving the PegIntron Pen Plus Rebetol for Hepatitis C (Study P04244)(COMPLETED)
The current gold standard for treatment of chronic hepatitis C is pegylated interferon plus ribavirin. Drug administration accuracy and ease of use will definitely determine treatment effectiveness.
- Trial name
- NCT00705263
- Testing
- Peginterferon alfa-2b (SCH 54031), Ribavirin (SCH 18908)
- Volunteers
- 113 people
- Sponsor
- Schering-Plough
Hepatitis C Virus
Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection
This study is to evaluate the safety, tolerability, and antiviral activity of sofosbuvir (SOF) with ribavirin (RBV) in Egyptian adults with chronic genotype 4 hepatitis C virus (HCV) infection.
- Trial name
- NCT01713283
- Testing
- SOF, RBV
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
This prospective observational study will evaluate the efficacy and safety of two approved pegylated interferon-based direct acting antiviral triple therapies in patients with chronic hepatitis C genotype 1.
- Trial name
- NCT01508130
- Where
- 66 sites in United States, Puerto Rico
- Volunteers
- 672 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
Drug Interaction & Methadone & Buprenorphine
The purpose of this study is to assess the effects of steady state DCV/ASV/BMS-791325 fixed dose combination (FDC) + 75mg BMS-791325 on the Pharmacokinetics (PK) of Methadone in subjects with the stable dose of Methadone and on…
- Trial name
- NCT02045693
- Testing
- Methadone, DCV 3DAA FDC, BMS-791325
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic
Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection
The purpose of this open-label study is to assess the safety, tolerability, antiviral activity, genotype resistance associated with virological failure, pharmacokinetics and pharmacodynamics of two dose regimens of miravirsen in…
- Trial name
- NCT01872936
- Testing
- Miravirsen, Telaprevir, Ribavirin
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 20 people
- Sponsor
- Santaris Pharma A/S
Hepatitis C
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
The objective of this trial is to collect evidence for the safety and efficacy of 24 weeks of treatment with BI 201335 240 mg in combination with 24 or 48 weeks of Pegylated Interferon (PegIFN) and ribavirin (RBV) in treatment…
- Trial name
- NCT01330316
- Testing
- BI 201335, PegIFN/RBV
- Where
- 87 sites in United States, Austria and 13 more
- Volunteers
- 119 people
- Sponsor
- Boehringer Ingelheim
Hepatitis C Virus
Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
The purpose of this study is to evaluate the efficacy of 6 or 8 weeks of treatment regimen containing simeprevir (SMV), daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naive (not having received treatment with any approved or…
- Trial name
- ACCORDION-1 (NCT02349048)
- Testing
- Simeprevir 150 mg, Daclatasvir 60 mg, Sofosbuvir 400 mg
- Where
- 8 sites in United States, Canada
- Volunteers
- 68 people
- Sponsor
- Janssen Research & Development, LLC
Hepatitis C, Chronic
Gilead Sustained Virologic Response (SVR) Registry
This Registry is designed to provide long term clinical and virologic follow up in participants who have achieved sustained virologic response (SVR) while participating in a previous Gilead sponsored hepatitis C virus (HCV)…
- Trial name
- NCT01457755
- Where
- 325 sites in United States, Australia and 15 more
- Volunteers
- 6,625 people
- Sponsor
- Gilead Sciences
Hepatitis C
Study of AVI-4065 in Healthy Volunteers and Chronic Active HCV Patients
Chronic active hepatitis C viral infections are difficult to treat: current drug therapies can result in severe side effects that some patients will not tolerate.
- Trial name
- NCT00229749
- Testing
- AVI-4065 Injection
- Volunteers
- 80 people
- Sponsor
- Sarepta Therapeutics, Inc.
HCV Infection
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection
The purpose of this study was to investigate the safety, tolerability, pharmacokinetics (PK), and antiviral activity of multiple doses of ACH-0137171 in participants with chronic hepatitis C virus (HCV) infection.
- Trial name
- NCT00401947
- Testing
- ACH-0137171
- Where
- 9 sites in United States, Germany and 1 more
- Volunteers
- 30 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hepatitis C, Chronic
PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)
This observational study will assess predictors of early on-treatment and sustained virological response in treatment-naïve patients with chronic hepatitis C initiated on treatment with Pegasys (peginterferon alfa-2a) and…
- Trial name
- NCT01070550
- Testing
- Peginterferon alfa-2a (Pegasys®)
- Where
- 266 sites in Austria, Brazil and 12 more
- Volunteers
- 4,680 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
The purpose of this study is to treat human immunodeficiency virus (HIV) and Hepatitis C Virus (HCV) co-infected subjects with telaprevir, pegylated interferon alfa-2a (Peg-IFN-alfa-2a), and ribavirin (RBV) to achieve…
- Trial name
- NCT01467479
- Testing
- Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a
- Where
- 59 sites in United States, Canada and 3 more
- Volunteers
- 185 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Liver Transplantation, Hepatitis C, Chronic
Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)
This is an exploratory study and is a Phase 3, single-arm, multi-center, open-label study of pegylated interferon alfa-2b, PEG-IFN alpha-2b (PEG-Intron) and ribavirin (RBV) to determine the sustained virologic response (SVR) at…
- Conditions
- Liver Transplantation, Hepatitis C, Chronic, Liver Cirrhosis
- Trial name
- NCT00378599
- Testing
- Combination of (a) pegylated interferon alfa-2b and (b) rebetol
- Volunteers
- 125 people
- Sponsor
- Merck Sharp & Dohme LLC